Baidu
map

Brit J Heamatol:血清BDNF浓度预测多发性骨髓瘤患者的多发性神经病和总生存期

2020-07-01 MedSci原创 MedSci原创

BDNF水平可能在预测MM患者CIPN中起预后作用,且是一个有用的生物标志物。

脑源性神经营养因子(BDNF)是一种对神经元和血管功能具有多个方面效应的蛋白质。然而,其在多发性骨髓瘤(MM)中的预后和功能仍然未知。

近日,血液系统疾病权威杂志British Journal of Haematology上发表了一篇研究文章,在这项研究中,研究人员调查了BDNF对化疗引起的周围神经病(CIPN)风险和临床结局的影响。研究组包括91名接受硼替佐米和/或沙利度胺为主的化疗的新诊断MM患者。研究人员使用ELISA进行血清中BDNF的检测。根据CTCAE标准v5对多发性神经病进行了评估。

研究人员观察到BDNF浓度与多发性神经病的严重程度相关(P=0.0463)。对治疗有反应的患者具有较高的BDNF水平(P=0.0326),并且证明BDNF是预测八个治疗周期后缺乏反应的有用标志物(敏感性为–100%,特异性为–61.5%,P=0.0142)。此外,该标记物在诊断CIPN中具有显著的诊断价值(敏感性为–76%,特异性为–71.43%;曲线下面积(AUC)=0.77,95%置信区间(CI):0.64-0.88;P<0.0001)。低BDNF水平是与总生存期(OS)降低相关的独立的不利预后因素(风险比(HR)=2.79,P=0.0470)。

总之,BDNF水平可能在预测MM患者CIPN中起预后作用,且是一个有用的生物标志物。

原始出处:

Aneta Szudy‐Szczyrek.et al.Serum brain‐derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients.british journal of haematology.2020.https://doi.org/10.1111/bjh.16862

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1709215, encodeId=57151e0921553, content=<a href='/topic/show?id=dd2f43108e4' target=_blank style='color:#2F92EE;'>#多发性神经病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43108, encryptionId=dd2f43108e4, topicName=多发性神经病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849831619609, createdName=ms3892185887221420, createdTime=Sun Jan 31 15:39:19 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890135, encodeId=08ba18901357f, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 29 03:39:19 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378247, encodeId=4f7213e82475b, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423849, encodeId=cc2f14238497b, content=<a href='/topic/show?id=ec6d3299f3' target=_blank style='color:#2F92EE;'>#BDNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3299, encryptionId=ec6d3299f3, topicName=BDNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ba3855050, createdName=apoenzyme, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491370, encodeId=e08814913e0dd, content=<a href='/topic/show?id=5316e4387aa' target=_blank style='color:#2F92EE;'>#神经病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74387, encryptionId=5316e4387aa, topicName=神经病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ab48885684, createdName=axin012, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516025, encodeId=2028151602545, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544650, encodeId=d2d5154465062, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1709215, encodeId=57151e0921553, content=<a href='/topic/show?id=dd2f43108e4' target=_blank style='color:#2F92EE;'>#多发性神经病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43108, encryptionId=dd2f43108e4, topicName=多发性神经病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849831619609, createdName=ms3892185887221420, createdTime=Sun Jan 31 15:39:19 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890135, encodeId=08ba18901357f, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 29 03:39:19 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378247, encodeId=4f7213e82475b, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423849, encodeId=cc2f14238497b, content=<a href='/topic/show?id=ec6d3299f3' target=_blank style='color:#2F92EE;'>#BDNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3299, encryptionId=ec6d3299f3, topicName=BDNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ba3855050, createdName=apoenzyme, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491370, encodeId=e08814913e0dd, content=<a href='/topic/show?id=5316e4387aa' target=_blank style='color:#2F92EE;'>#神经病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74387, encryptionId=5316e4387aa, topicName=神经病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ab48885684, createdName=axin012, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516025, encodeId=2028151602545, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544650, encodeId=d2d5154465062, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1709215, encodeId=57151e0921553, content=<a href='/topic/show?id=dd2f43108e4' target=_blank style='color:#2F92EE;'>#多发性神经病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43108, encryptionId=dd2f43108e4, topicName=多发性神经病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849831619609, createdName=ms3892185887221420, createdTime=Sun Jan 31 15:39:19 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890135, encodeId=08ba18901357f, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 29 03:39:19 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378247, encodeId=4f7213e82475b, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423849, encodeId=cc2f14238497b, content=<a href='/topic/show?id=ec6d3299f3' target=_blank style='color:#2F92EE;'>#BDNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3299, encryptionId=ec6d3299f3, topicName=BDNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ba3855050, createdName=apoenzyme, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491370, encodeId=e08814913e0dd, content=<a href='/topic/show?id=5316e4387aa' target=_blank style='color:#2F92EE;'>#神经病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74387, encryptionId=5316e4387aa, topicName=神经病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ab48885684, createdName=axin012, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516025, encodeId=2028151602545, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544650, encodeId=d2d5154465062, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1709215, encodeId=57151e0921553, content=<a href='/topic/show?id=dd2f43108e4' target=_blank style='color:#2F92EE;'>#多发性神经病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43108, encryptionId=dd2f43108e4, topicName=多发性神经病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849831619609, createdName=ms3892185887221420, createdTime=Sun Jan 31 15:39:19 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890135, encodeId=08ba18901357f, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 29 03:39:19 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378247, encodeId=4f7213e82475b, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423849, encodeId=cc2f14238497b, content=<a href='/topic/show?id=ec6d3299f3' target=_blank style='color:#2F92EE;'>#BDNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3299, encryptionId=ec6d3299f3, topicName=BDNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ba3855050, createdName=apoenzyme, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491370, encodeId=e08814913e0dd, content=<a href='/topic/show?id=5316e4387aa' target=_blank style='color:#2F92EE;'>#神经病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74387, encryptionId=5316e4387aa, topicName=神经病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ab48885684, createdName=axin012, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516025, encodeId=2028151602545, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544650, encodeId=d2d5154465062, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=)]
    2020-07-03 apoenzyme
  5. [GetPortalCommentsPageByObjectIdResponse(id=1709215, encodeId=57151e0921553, content=<a href='/topic/show?id=dd2f43108e4' target=_blank style='color:#2F92EE;'>#多发性神经病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43108, encryptionId=dd2f43108e4, topicName=多发性神经病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849831619609, createdName=ms3892185887221420, createdTime=Sun Jan 31 15:39:19 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890135, encodeId=08ba18901357f, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 29 03:39:19 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378247, encodeId=4f7213e82475b, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423849, encodeId=cc2f14238497b, content=<a href='/topic/show?id=ec6d3299f3' target=_blank style='color:#2F92EE;'>#BDNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3299, encryptionId=ec6d3299f3, topicName=BDNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ba3855050, createdName=apoenzyme, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491370, encodeId=e08814913e0dd, content=<a href='/topic/show?id=5316e4387aa' target=_blank style='color:#2F92EE;'>#神经病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74387, encryptionId=5316e4387aa, topicName=神经病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ab48885684, createdName=axin012, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516025, encodeId=2028151602545, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544650, encodeId=d2d5154465062, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=)]
    2020-07-03 axin012
  6. [GetPortalCommentsPageByObjectIdResponse(id=1709215, encodeId=57151e0921553, content=<a href='/topic/show?id=dd2f43108e4' target=_blank style='color:#2F92EE;'>#多发性神经病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43108, encryptionId=dd2f43108e4, topicName=多发性神经病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849831619609, createdName=ms3892185887221420, createdTime=Sun Jan 31 15:39:19 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890135, encodeId=08ba18901357f, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 29 03:39:19 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378247, encodeId=4f7213e82475b, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423849, encodeId=cc2f14238497b, content=<a href='/topic/show?id=ec6d3299f3' target=_blank style='color:#2F92EE;'>#BDNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3299, encryptionId=ec6d3299f3, topicName=BDNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ba3855050, createdName=apoenzyme, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491370, encodeId=e08814913e0dd, content=<a href='/topic/show?id=5316e4387aa' target=_blank style='color:#2F92EE;'>#神经病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74387, encryptionId=5316e4387aa, topicName=神经病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ab48885684, createdName=axin012, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516025, encodeId=2028151602545, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544650, encodeId=d2d5154465062, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1709215, encodeId=57151e0921553, content=<a href='/topic/show?id=dd2f43108e4' target=_blank style='color:#2F92EE;'>#多发性神经病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43108, encryptionId=dd2f43108e4, topicName=多发性神经病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849831619609, createdName=ms3892185887221420, createdTime=Sun Jan 31 15:39:19 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890135, encodeId=08ba18901357f, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 29 03:39:19 CST 2020, time=2020-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378247, encodeId=4f7213e82475b, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423849, encodeId=cc2f14238497b, content=<a href='/topic/show?id=ec6d3299f3' target=_blank style='color:#2F92EE;'>#BDNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3299, encryptionId=ec6d3299f3, topicName=BDNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ba3855050, createdName=apoenzyme, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491370, encodeId=e08814913e0dd, content=<a href='/topic/show?id=5316e4387aa' target=_blank style='color:#2F92EE;'>#神经病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74387, encryptionId=5316e4387aa, topicName=神经病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ab48885684, createdName=axin012, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516025, encodeId=2028151602545, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544650, encodeId=d2d5154465062, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Jul 03 03:39:19 CST 2020, time=2020-07-03, status=1, ipAttribution=)]

相关资讯

Blood:在多发性骨髓瘤中,单克隆免疫球蛋白促进骨丢失

骨髓瘤合并骨病患者的单克隆免疫球蛋白的IgG Fc糖基化减少,促进破骨细胞分化;在骨髓瘤小鼠模型中,用N-乙酰甘露糖胺治疗可增加IgG唾液酸苷化,减少骨髓瘤溶骨损伤的数量和肿瘤负荷。

Cell Death Dis:西达本胺通过表观遗传修饰抑制细胞自噬发挥抗骨髓瘤活性

细胞自噬过程会导致异常的细胞质组分出现自噬小体依赖性的溶酶体降解反应,其涉及了一系列以如LC3B1-3在内的自噬相关(ATG)蛋白为核心组成的细胞膜动态重塑过程。

Blood:III试验:不同方案治疗的骨髓瘤患者的血栓形成情况

新确诊的接受治疗的骨髓瘤患者的VTE风险较高,通过IMWG指导的血栓预防仅可轻度降低该风险。 沙利度胺和来那度胺治疗的静脉血栓栓塞风险相同;在本试验中,VTE与PFS或OS 降低无关。

强生的CAR-T疗法JNJ-4528用于多发性骨髓瘤:86%的患者获得完全缓解

Ib/II期研究CARTITUDE-1的数据显示,所有患者对该疗法均有应答,其中86%的患者在11.5个月的中位随访中获得了完全缓解,在第9个月时86%的患者无进展存活。

FDA批准重磅抗癌靶向药达雷妥尤单抗皮下注射制剂!给药由3小时缩短至5分钟!

2020年5月1日,美国FDA批准daratumumab(中文商品名:兆珂®,Darzalex,达雷妥尤单抗)和透明质酸酶-fihj(Darzalex Faspro)的皮下注射制剂,用于患有新

Baidu
map
Baidu
map
Baidu
map